For INVESTORS & INVESTMENT TEAMS
Invest Smarter in Science-Driven Opportunities
You’ve seen the pitch decks. The data rooms. The glowing reviews from technical founders. But how do you know what’s real—and what’s ready?
At Innoventyx, we help investors make more confident decisions in the biotech and pharmaceutical space. Whether you’re reviewing a seed-stage concept or a growth-stage asset nearing IND, we dive deep into the science, the IP, and the execution plan—so you don’t have to wonder if you’re missing something.
What We Do
Deep Diligence
We evaluate intellectual property, preclinical programs, and the chemistry manufacturing controls (CMC) strategy behind a drug candidate. This includes assessing the robustness, cost-effectiveness, and scalability of the manufacturing process—critical factors that impact timelines, regulatory success, and downstream valuation.
Red Flag Audits
We perform site-level evaluations of labs and manufacturing facilities—either in person or remotely—to uncover operational risks that may compromise product quality or delay development. This includes assessing safety and manufacturing history records, reviewing documentation practices, and identifying gaps in SOP adherence, material handling, or chain of custody that could affect regulatory approval or investor confidence.
IP Landscape Analysis
We assess the strength, scope, and strategic value of a company’s intellectual property. This includes evaluating how broad or narrow the claims are, identifying weaknesses or gaps in the patent filings, and comparing the invention to competing FDA-approved drugs and drugs in development. We also consider freedom-to-operate risks, potential for patent challenges, and alignment between the IP strategy and the company’s development and commercialization plans.
The result: a clearer picture of how defensible the IP is—and how much it really supports the drug candidate’s potential valuation.
Strategic Commercialization Insights
We assess how unique and versatile a drug candidate or research program truly is. This includes determining whether it represents a platform—for example, if the underlying chemistry or process can generate multiple drug types (such as small molecules or antibody-drug conjugates) or address more than one disease indication.
We also evaluate key commercialization drivers, such as:
- Intended use (monotherapy or combination therapy)
- Route of administration (oral, infusion, subcutaneous, topical, etc.)
- Target validation (whether the biological target is clinically validated, novel, or still exploratory)
These factors together impact licensing potential, development risk, and future market value—providing investors with a more accurate view of the opportunity.
Why Investors Choose Innoventyx
30 years in drug discovery, drug development, and biotech leadership
Deep technical and IP due diligence backed by real-world R&D execution
Trusted by NIH, investors, PE groups, family offices, and global accelerators
Proven ability to spot red flags early and validate scientific claims before capital is deployed
Call Us
(225) 334-8194
Hours
By Appointment
innoventyx.com/chat
Office
7566 Kingsley Drive
Denham Springs, LA 70706


